| [1] |
SAYEGH MH, CARPENTER CB.Transplantation 50 years later--progress, challenges, and promises[J]. N Engl J Med, 2004, 351(26): 2761-2766.
|
| [2] |
HALLORAN PF.Immunosuppressive drugs for kidney transplantation[J]. N Engl J Med, 2004,351(26): 2715-2729.
|
| [3] |
CLASE CM,MAHALATI K, KIBERD BA, et al.Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling[J] . Am J Transplant, 2002, 2(8): 789-795.
|
| [4] |
UNDRE NA, VAN HOOFF J, CHRISTINANS M, et al.Low systemic exposure to tacrolimus correlates with acute rejection[J].Transplant Proc, 1999,31(1-2): 296-298.
|
| [5] |
NANKIVELL BJ, BORROWS RJ, FUNG CJ, et al.The natural history of chronic allograft nephropathy[J]. N Engl J Med, 2003,349(24): 2326-2333.
|
| [6] |
DAVIDSON JA, WILKINSON A, International Expert Panel on New-Onset Diabetes after Transplantation. New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist's view[J]. Diabetes Care, 2004, 27(3): 805-812.
|
| [7] |
DE JONGE H, NAESENS M, KUYPERS DR.New insights into the pharmacokinetics and pharmacody-namics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation[J]. Ther Drug Monit, 2009,31(4): 416-435.
|
| [8] |
HOLT DW.Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation[J]. Curr Opin Nephrol Hypertens, 2002, 11(6): 657-663.
|
| [9] |
DIAZ-MOLINA B, TAVIRA B, LAMBERT JL, et al.Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation[J]. Transplant Proc, 2012, 44(9):2635-2638.
|
| [10] |
PROVENZANI A, SANTEUSANIO A, MATHIS E, et al.Pharmacogenetic considerations for opti-mizing tacrolimus dosing in liver and kidney transplant patients[J]. World J Gastroenterol, 2013, 19(48): 9156-9173.
|
| [11] |
MIURA M, SATOH S, KAGAYA H, et al.Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients[J]. Pharmacogenomics, 2011,12(7):977-984.
|
| [12] |
BIRDWELL KA, GRADY B, CHOI L, et al.The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients[J]. Pharmacogenet Genomics, 2012, 22(1): 32-42.
|
| [13] |
FUKUSHIMA-UESAKA H, SAITO Y, WATANABE H, et al.Haplotypes of CYP3A4 and their close 24 linkage with CYP3A5 haplotypes in a Japanese population[J]. Hum Mutat, 2004, 23(1): 100.
|
| [14] |
MACPHEE IA, FREDERICKS S, MOHAMED M, et al.Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians[J]. Transplantation, 2005, 79(4): 499-502.
|
| [15] |
BARANSKA M, DZIANKOWSKA-BARTKOWIAK B, WASCZYKOWSKA E, et al.Significance of genetic polymorphism of CYP2D6 in the pathogenesis of systemic sclerosis[J]. Pharmacol Rep, 2012, 64(2): 336-342.
|
| [16] |
SOYAMA A, KUBO T, MIYAJIMA A, et al.Novel nonsynonymous single nucleotide polymorphisms in the CYP2D6 gene[J]. Drug Metab Pharmacokinet, 2004, 19(4): 313-319.
|
| [17] |
ZHOU SF.Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part Ⅰ[J]. Clin Pharmacokinet, 2009, 48(11): 689-723.
|
| [18] |
TEH LK, BERTILSSON L.Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance[J]. Drug Metab Pharmacokinet, 2012, 27(1): 55-67.
|
| [19] |
SUZUKI Y, FUKUI N, TSUNEYAMA N, et al.Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients[J]. Hum Psychopharmacol, 2012, 27(1): 43-46.
|
| [20] |
BALL SE, SCATINA J, KAO J, et al.Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4[J]. Clin Pharmacol Ther, 1999, 66(3): 288-294.
|
| [21] |
燕贞,吴逸明,吴拥军. CYP2D6*10 多态性和肺癌易感性[J]. 中国医学科学院学报, 2008, 30(5):564-568.
|
| [22] |
GLOWACKI F, LIONET A, BUOB D, et al.CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation[J]. Nephrol Dial Transplant , 2011, 26(9): 3046-3050.
|
| [23] |
KURZAWSKI M, DABROWSKA J, DZIEWA-NOWSKI K, et al.CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipient[J].Pharmacogenomics,2014,15(2):179-188.
|
| [24] |
SAKUYAMA K, SASAKI T, UJIIE S, et al.Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57)[J]. Drug Metab Dispos, 2008, 36(12): 2460-2467.
|
